Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy

被引:1
作者
Wang, Weiwei [1 ]
Qu, Chaoyi [1 ]
Yan, Huanhuan [1 ]
机构
[1] Xian Peoples Hosp, Shaanxi Eye Hosp, Xian Hosp 4, Xian, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词
proliferative diabetic retinopathy; vitrectomy; conbercept; intravitreal; network meta-analysis; PARS-PLANA VITRECTOMY; LINEAR MIXED MODELS; SYSTEMATIC REVIEWS; HEALTH-CARE; INCONSISTENCY; BEVACIZUMAB; PRETREATMENT; RANIBIZUMAB;
D O I
10.3389/fendo.2023.1098165
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PurposeIntravitreal Conbercept (IVC) has been shown to be effective in treating proliferative diabetic retinopathy (PDR) as an adjuvant in pars plana vitrectomy (PPV); however, the best timing of IVC injection remains unknown. This network meta-analysis (NMA) sought to ascertain the comparative efficacy of different timings of IVC injection as an adjuvant to PPV on PDR. MethodsA comprehensive literature search was conducted in PubMed, EMBASE, and the Cochrane Library to identify relevant studies published before August 11, 2022. According to the mean time of IVC injection before PPV, the strategy was defined as very long interval if it was > 7 days but <= 9 days, long interval if it was > 5 days but <= 7 days, mid interval if it was > 3 days but <= 5 days, and short interval if it was <= 3 days, respectively. The strategy was defined as perioperative IVC if IVC was injected both before and at the end of PPV, and the strategy was intraoperative IVC if injected immediately at the end of PPV. The mean difference (MD) and odds ratio (OR) with corresponding 95% confidence interval (CI) for continuous and binary variables, respectively, were computed through network meta-analysis using Stata 14.0 MP. ResultsEighteen studies involving 1149 patients were included. There was no statistical difference between intraoperative IVC and control in treating PDR. Except for a very long interval, preoperative IVC significantly shortened operation time, and reduced intraoperative bleeding and iatrogenic retinal breaks. Long and short intervals reduced endodiathermy application, and mid and short intervals reduced postoperative vitreous hemorrhage. Moreover, long and mid intervals improved BCVA and central macular thickness. However, very long interval was associated with an increased risk of postoperative vitreous hemorrhage (RR: 3.27, 95%CI: 1.84 to 5.83). Moreover, mid interval was better than intraoperative IVC in shortening operation time (MD: -19.74, 95%CI: -33.31 to -6.17). ConclusionsThere are no discernible effects of intraoperative IVC on PDR, but preoperative IVC, except for very long interval, is an effective adjuvant to PPV for treating PDR.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy
    Li Bing
    Li Meng-Da
    Ye Jun-Jie
    Chen Zhe
    Guo Zi-Jian
    Di Yu
    CHINESE MEDICAL JOURNAL, 2020, 133 (06) : 664 - 669
  • [32] Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study
    Wang, Jing
    Jiang, Peng-Fei
    Liu, Min
    Kou, Ming-Rong
    Lei, Jia-Ying
    Yu, Xiao-Ting
    Zhao, Ying
    Wang, Hong
    Zhang, Lin-Na
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (04)
  • [33] Conbercept and Ranibizumab Pretreatments in Vitrectomy with Silicone Oil Infusion for Severe Diabetic Retinopathy
    Yang, Kai-Bo
    Zhang, Han
    Li, Si-Jia
    Cao, Jiao-Jiao
    Cheng, Lu-Na
    Lin, Yu-xi
    Tian, Zhe-Chen
    Li, Jun
    Gu, Feng
    Liu, Zhe-Li
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2019, 35 (03) : 161 - 167
  • [34] Perioperative Use of Bevacizumab in Vitrectomy for Proliferative Diabetic Retinopathy: A Literature review
    Falavarjani, Khalil Ghasemi
    Modarres, Mehdi
    IRANIAN JOURNAL OF OPHTHALMOLOGY, 2010, 22 (02): : 5 - 12
  • [35] Efficacy and Safety of Various Treatments for Proliferative Diabetic Retinopathy: A Systematic Review and Network Meta-Analysis
    Zhang, Bo
    Zhou, Zhulin
    Zhang, Bingjie
    Wang, Dan
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [36] Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress
    Xia, Jian-Ping
    Liu, Sheng-Qiang
    Wang, Shuai
    LIFE SCIENCES, 2021, 265
  • [37] Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy
    Chen, Hui-Jin
    Wang, Chang-Guan
    Dou, Hong-Liang
    Feng, Xue-Feng
    Xu, Yi-Min
    Ma, Zhi-Zhong
    ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (01) : 82 - 89
  • [38] Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis
    Fallico, Matteo
    Maugeri, Andrea
    Lotery, Andrew
    Longo, Antonio
    Bonfiglio, Vincenza
    Russo, Andrea
    Avitabile, Teresio
    Pulvirenti, Alfredo
    Furino, Claudio
    Cennamo, Gilda
    Barchitta, Martina
    Agodi, Antonella
    Reibaldi, Michele
    ACTA OPHTHALMOLOGICA, 2021, 99 (06) : E795 - E805
  • [39] Prospective Comparison of Surgery Outcome Between Preoperative and Intraoperative Intravitreal Injection of Ranibizumab for Vitrectomy in Proliferative Diabetic Retinopathy Patients
    Li, Siying
    Tang, Jiyang
    Han, Xinyao
    Wang, Zongyi
    Zhang, Linqi
    Zhao, Mingwei
    Qu, Jinfeng
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (05) : 1833 - 1845
  • [40] Vitrectomy results in proliferative diabetic retinopathy
    Luan, Jie
    Ando, Fumitaka
    Hirose, Hirosi
    Yasui, Osumu
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2008, 1 (04): : 356 - 358